...
首页> 外文期刊>HIV medicine >Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration
【24h】

Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration

机译:比较瞬时弹性成像(FibroScan),FibroTest,APRI和将这些非侵入性测试相结合的两种算法对HIV / HCV合并感染患者的肝纤维化分期:ANRS CO13 HEPAVIH和FIBROSTIC合作

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objectives: Combining noninvasive tests increases diagnostic accuracy for staging liver fibrosis in hepatitis C virus (HCV)-infected patients, but this strategy remains to be validated in HIV/HCV coinfection. We compared the performances of transient elastography (TE), Fibrotest (FT), the aspartate aminotransferase-to-platelet ratio index (APRI) and two algorithms combining TE and FT (Castera) or APRI and FT (SAFE) in HIV/HCV coinfection. Methods: One hundred and sixteen HIV/HCV-coinfected patients (64% male; median age 44 years) enrolled in two French multicentre studies (the HEPAVIH cohort and FIBROSTIC) for whom TE, FT and APRI data were available were included in the study. Diagnostic accuracies for significant fibrosis (METAVIR F≥2) and cirrhosis (F4) were evaluated by measuring the area under the receiver-operating characteristic curve (AUROC) and calculating percentages of correctly classified (CC) patients, taking liver biopsy as a reference. Results: For F≥2, both TE and FT (AUROC=0.87 and 0.85, respectively) had a better diagnostic performance than APRI (AUROC=0.71; P<0.005). Although the percentage of CC patients was significantly higher with Castera's algorithm than with SAFE (61.2% vs. 31.9%, respectively; P<0.0001), this percentage was lower than that for TE (80.2%; P<0.0001) or FT (73.3%; P<0.0001) taken separately. For F4, TE (AUROC=0.92) had a better performance than FT (AUROC=0.78; P=0.005) or APRI (AUROC=0.73; P=0.025). Although the percentage of CC patients was significantly higher with the SAFE algorithm than with Castera's (76.7% vs. 68.1%, respectively; P<0.050), it was still lower than that for TE (85.3%; P<0.033). Conclusions: In HIV/HCV-coinfected patients, TE and FT have a similar diagnostic accuracy for significant fibrosis, whereas for cirrhosis TE has the best accuracy. The use of the SAFE and Castera algorithms does not seem to improve diagnostic performance.
机译:目标:结合非侵入性检测可提高对丙型肝炎病毒(HCV)感染患者进行肝纤维化分期的诊断准确性,但该策略在HIV / HCV合并感染中仍有待验证。我们比较了瞬时弹性成像(TE),Fibrotest(FT),天冬氨酸氨基转移酶与血小板比率指数(APRI)和结合TE和FT(Castera)或APRI和FT(SAFE)的两种算法在HIV / HCV合并感染中的表现。方法:116名HIV / HCV合并感染患者(男性占64%;中位年龄44岁)参加了两项法国多中心研究(HEPAVIH队列和FIBROSTIC),该研究包括TE,FT和APRI数据。通过测量接受者手术特征曲线(AUROC)下的面积并计算正确分类的(CC)患者的百分比,并以肝活检为参考,评估重大纤维化(METAVIRF≥2)和肝硬化(F4)的诊断准确性。结果:对于F≥2,TE和FT(AUROC分别为0.87和0.85)均比APRI(AUROC = 0.71; P <0.005)更好。尽管使用Castera算法的CC患者百分比显着高于SAFE(分别为61.2%和31.9%; P <0.0001),但该百分比低于TE(80.2%; P <0.0001)或FT(73.3) %; P <0.0001)分开计算。对于F4,TE(AUROC = 0.92)的性能优于FT(AUROC = 0.78; P = 0.005)或APRI(AUROC = 0.73; P = 0.025)。尽管使用SAFE算法的CC患者百分比显着高于Castera(分别为76.7%和68.1%; P <0.050),但仍低于TE患者(85.3%; P <0.033)。结论:在HIV / HCV合并感染的患者中,TE和FT对严重纤维化的诊断准确性相似,而对于肝硬化,TE的准确性最高。 SAFE和Castera算法的使用似乎并未改善诊断性能。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号